Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids
Contact
Description
This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway. This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose.
Eligibility and criteria
What to expect
Participants in the research will:
- Receive a study drug called tegavivint
- Complete frequent clinic visits at CHOP
- Have frequent blood tests
- Have DEXA scans to measure your bone density
- Have knee x-rays if under the age of 18
- Have extra or leftover tissue collected if they have a biopsy as part of regular cancer care
- Have periodic electrocardiograms (ECGs)
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.